OBJECTIVE: To estimate annual per-patient health services utilization and costs of retinitis pigmentosa (RP) in the United States. METHODS: A retrospective claims analysis of patients with RP (N = 2990) and a 1:1 exactly matched cohort of non-RP patients was conducted using the MarketScan Commercial and Medicare Supplemental Databases. Individuals were continuously enrolled in a commercial health plan or employer-sponsored health insurance for at least 1 year. The following annual outcomes were analyzed using nonlinear multivariate models: inpatient hospital admissions, inpatient hospital days, emergency department visits, outpatient physician visits, and prescription drug refills and inpatient and outpatient medical, pharmacy, and total health care costs. RESULTS: Patients with RP had 0.04 more hospital admissions (P < .001), 0.19 more inpatient hospital days (P < .02), 0.05 more emergency department visits (P < .01), 2.74 more outpatient visits (P < .001), and 2.18 additional prescription drug fills (P < .001) annually compared with their non-RP counterparts. Health care expenditures were significantly higher for patients with RP, who cost $894, $4855, and $452 more for inpatient, outpatient, and pharmacy services, respectively (P < .001). Overall health care costs were $7317 more per patient per year in the RP cohort, with expenditures varying considerably by age. CONCLUSIONS: Patients with RP consume substantially greater amounts of health services with significantly higher health care costs. CLINICAL RELEVANCE: Treatments that slow, halt, or possibly restore RP-related vision loss may prove cost-effective for payers and society.
OBJECTIVE: To estimate annual per-patient health services utilization and costs of retinitis pigmentosa (RP) in the United States. METHODS: A retrospective claims analysis of patients with RP (N = 2990) and a 1:1 exactly matched cohort of non-RP patients was conducted using the MarketScan Commercial and Medicare Supplemental Databases. Individuals were continuously enrolled in a commercial health plan or employer-sponsored health insurance for at least 1 year. The following annual outcomes were analyzed using nonlinear multivariate models: inpatient hospital admissions, inpatient hospital days, emergency department visits, outpatient physician visits, and prescription drug refills and inpatient and outpatient medical, pharmacy, and total health care costs. RESULTS:Patients with RP had 0.04 more hospital admissions (P < .001), 0.19 more inpatient hospital days (P < .02), 0.05 more emergency department visits (P < .01), 2.74 more outpatient visits (P < .001), and 2.18 additional prescription drug fills (P < .001) annually compared with their non-RP counterparts. Health care expenditures were significantly higher for patients with RP, who cost $894, $4855, and $452 more for inpatient, outpatient, and pharmacy services, respectively (P < .001). Overall health care costs were $7317 more per patient per year in the RP cohort, with expenditures varying considerably by age. CONCLUSIONS:Patients with RP consume substantially greater amounts of health services with significantly higher health care costs. CLINICAL RELEVANCE: Treatments that slow, halt, or possibly restore RP-related vision loss may prove cost-effective for payers and society.
Authors: K Thiran Jayasundera; Rebhi O Abuzaitoun; Gabrielle D Lacy; Maria Fernanda Abalem; Gregory M Saltzman; Thomas A Ciulla; Mark W Johnson Journal: Am J Ophthalmol Date: 2021-08-22 Impact factor: 5.258
Authors: Qing Chang; Evgeny Berdyshev; Dingcai Cao; Joseph D Bogaard; Jerry J White; Siquan Chen; Ravi Shah; Wenbo Mu; Rita Grantner; Sam Bettis; Michael A Grassi Journal: J Biol Chem Date: 2014-02-11 Impact factor: 5.157
Authors: Anil Vaidya; Elio Borgonovi; Rod S Taylor; José-Alain Sahel; Stanislao Rizzo; Paulo Eduardo Stanga; Amit Kukreja; Peter Walter Journal: BMC Ophthalmol Date: 2014-04-14 Impact factor: 2.209
Authors: Tobias Eisenberger; Christine Neuhaus; Arif O Khan; Christian Decker; Markus N Preising; Christoph Friedburg; Anika Bieg; Martin Gliem; Peter Charbel Issa; Frank G Holz; Shahid M Baig; Yorck Hellenbroich; Alberto Galvez; Konrad Platzer; Bernd Wollnik; Nadja Laddach; Saeed Reza Ghaffari; Maryam Rafati; Elke Botzenhart; Sigrid Tinschert; Doris Börger; Axel Bohring; Julia Schreml; Stefani Körtge-Jung; Chayim Schell-Apacik; Khadijah Bakur; Jumana Y Al-Aama; Teresa Neuhann; Peter Herkenrath; Gudrun Nürnberg; Peter Nürnberg; John S Davis; Andreas Gal; Carsten Bergmann; Birgit Lorenz; Hanno J Bolz Journal: PLoS One Date: 2013-11-12 Impact factor: 3.240